Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 87 publications
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial.
Journal: Journal of the American Heart Association
Published: August 31, 2026
Time Lost Is Myocardium Lost: Why Earlier Recognition of ATTR Cardiomyopathy Matters.
Journal: JACC. Advances
Published: July 07, 2026
Long-term effects of acoramidis on mortality in variant transthyretin amyloid cardiomyopathy, including p.Val142Ile: findings from the open-label extension of ATTRibute-CM.
Journal: European journal of heart failure
Published: June 15, 2026
Comorbidity Burden in Transthyretin Amyloidosis With Cardiomyopathy: Insights From the HELIOS-B Trial.
Journal: JACC. Heart failure
Published: March 27, 2026
Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM.
Journal: Future cardiology
Published: February 09, 2026
Redefining Disease Progression in ATTR-CM: Beyond Biomarkers to Patient-Centered Outcomes.
Journal: Journal of cardiac failure
Published: January 29, 2026
Anti-Fibril Depleters: The Dawn of a New Treatment Era in Transthyretin Amyloid Cardiomyopathy?
Journal: Circulation
Published: January 26, 2026
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.
Journal: JAMA cardiology
Published: November 08, 2025
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.
Journal: Journal of the American College of Cardiology
Published: October 31, 2025
Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review.
Journal: JACC. CardioOncology
Published: August 29, 2025
Last Updated: 09/26/2026